There are risks and benefits to any treatment for breast cancer. The Suppression of Ovarian Function Trial (SOFT) was designed to answer the question – would premenopausal women with early stage hormone receptor positive breast cancer benefit from ovarian suppression therapy in addition to Tamoxifen? This was an international trial presented by the International Breast Cancer Study Group from Bern, Switzerland.
The report that follows was researched and prepared by Connie Holdridge, Program Manager of Education and Survivorship at the Delaware Breast Cancer Coalition, following the San Antonio Breast Cancer Symposium in December 2014. Read on for the details.